Unique ID issued by UMIN | UMIN000014383 |
---|---|
Receipt number | R000016742 |
Scientific Title | A prospective randomized control study of combination therapy with low-dose methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease |
Date of disclosure of the study information | 2014/06/27 |
Last modified on | 2021/01/07 08:16:11 |
A prospective randomized control study of combination therapy with low-dose methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease
A prospective randomized control study of combination therapy with low-dose methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease
A prospective randomized control study of combination therapy with low-dose methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease
A prospective randomized control study of combination therapy with low-dose methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease
Japan |
Graves disease
Endocrinology and Metabolism | Pediatrics |
Others
NO
The objective of this study was to examine the efficacy and safety of combination therapy with methimazole and a cholesterol absorption inhibitor as for the initial treatment of childhood-onset Graves disease
Safety,Efficacy
The normalization rate of levels of free T4 and free T3 at the 4 weeks treatment.
Time to relief of hyperthyroid symptoms
The normalization rate of levels of free T4 and free T3 at the 8, 12, and 24 weeks treatment.
Change of levels of TRAb, Total cholesterol, CPK and 25 hydroxy vitamin D
Interventional
Parallel
Randomized
Cluster
Open -but assessor(s) are blinded
Active
YES
Central registration
2
Treatment
Medicine |
methimazole
methimazole and a cholesterol absorption inhibitor (colestimide)
10 | years-old | <= |
16 | years-old | > |
Male and Female
1) Patients with newly diagnosed Graves' disease
2) Serum FT4 value more than 5.0 ng/dl
3) Written informed consent from the patients' parents or legal guardians.
1) Patients with thyrotoxic crisis
2) Patients who receive pharmacotherapy for diabetes, hepatic and renal disease
3) Medical history of Graves disease. Patients who have already used cholesterol absorption inhibitor.
4) Use of coumarin anticoagulants, digitalis, and bile acids preparations
5) Judged inappropriate for this study by the physicians.
80
1st name | |
Middle name | |
Last name | Keisuke Nagasaki |
Niigata University Medical & Dental Hospital
Pediatrics
1-757 Asahimachi-Dori, Chu-Ou-Ku, Niigata city, Niigata
025-227-2222
nagasaki@med.niigata-u.ac.jp
1st name | |
Middle name | |
Last name | Keisuke Nagasaki |
ABC Tx Group
Department of Pediatrics, Niigata University
1-757 Asahimachi-Dori, Chu-Ou-Ku, Niigata city, Niigata
025-227-2222
nagasaki@med.niigata-u.ac.jp
ABC Tx group
MEXT(Japan)
Japanese Governmental office
NO
新潟大学医歯学総合病院、都立小児総合医療センター、宮崎大学医学部附属病院、大阪大学医学部附属病院、あいち小児保健医療総合センター、久留米大学病院、群馬大学医学部附属病院、長崎大学病院、金沢医科大学病院、順天堂大学医学部附属順天堂医院、聖マリアンナ医科大学病院、東京医科歯科大学医学部附属病院、東邦大学医療センター大森病院、山形大学医学部附属病院、住友別子病院、川崎市立川崎病院、名古屋市立大学病院、京都府立医科大学附属病院、信州大学医学部附属病院、磐田市立総合病院、北里大学病院、神奈川県立こども医療センター、北海道大学病院、慶応義塾大学病院、国立病院機構 四国こどもとおとなの医療センター、岩手医科大学附属病院、東北大学病院、愛媛大学医学部附属病院
2014 | Year | 06 | Month | 27 | Day |
Unpublished
No longer recruiting
2014 | Year | 05 | Month | 12 | Day |
2013 | Year | 11 | Month | 13 | Day |
2014 | Year | 06 | Month | 27 | Day |
2020 | Year | 09 | Month | 30 | Day |
2014 | Year | 06 | Month | 26 | Day |
2021 | Year | 01 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016742
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |